A review of stability data for plasmid pharmaceuticals accross typical storage temperatures and handling conditions.
Side by side comparison of the differences between VGXI’s Highly Documented (HD) grade and full cGMP grade service levels for plasmid production.
In-depth review of the standard test method and inherent limitations for evaluating nucleic acid purity.
Case studies are presented to illustrate how much plasmid is required at each stage of manufacturing – from bulk production through fill/finish and product stability studies.
A review of five key qualities to look for when choosing a CMO to manufacture plasmid DNA for a clinical trial.
An overview of the typical steps and time required for completion of a GMP plasmid manufacturing campaign.
This white paper reviews how a common plasmid selection agent, Kanamycin, is removed during the VGXI purification process to levels that are undetectable by standard assay methods.
White paper reviewing process and quality improvements possible through the use of single-use systems in biopharmaceutical manufacturing.
VGXI’s Pre-Clinical Production Service uses the same patented manufacturing technology as our GMP production.
VGXI’s HD Production Service produces plasmids suitable for use as a raw material in cGMP viral vector manufacturing and toxicology studies.
VGXI's cGMP Production Service provides injectable-grade plasmid DNA suitable for human clinical trials and commercial supply.
Novel Method for RNA Quantification and Exclusion from Plasmid DNA Vector Purification Process Stream
Challenges of Production of Nanoplasmid™ with Large Gene Insert Using the HyperGRO™ Fermentation Process
High Quality Plasmid DNA Manufacturing for Ex-Vivo Protein Synthesis and Viral Vector Production for Gene Therapy
Large Scale Production of DNA Plasmids with Complex Gene Inserts